An observational study in Colitis, Ulcerative, sponsored by Pfizer. Active, not recruiting at 26 sites in United States. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Pfizer · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Colitis, Ulcerative by Pfizer — 2 open to participants now, 7 under way, 2 of them phase 3. Colitis, Ulcerative · Pfizer.
Among the 42 studies in Colitis, Ulcerative by Pfizer, this one is the 8th largest by enrollment of the 16 observational ones that give a count, is one of 2 that started in 2024, is one of 16 observational ones, and was the 39th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →2 of the 42 studies in Colitis, Ulcerative by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Australia, Canada and 7 more countries
Ages 2–11
Pfizer · Sites in United States, Japan, Poland and 2 more countries
Ages 12–17
By country, each count listing its studies:
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 300 is above the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 129 across the 24 interventional studies, 276 across the 16 observational. Of the 32 that completed or were terminated, 26 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
3 of the studies in Colitis, Ulcerative by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT06294925PfizerA Study to Learn About the Effectiveness of Etrasimod in People With Ulcerative Colitis | 2027-05-13 |
| NCT06398626PfizerAn Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis | 2027-10-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 42 studies in Colitis, Ulcerative by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this observational study is to learn about the effects of etrasimod as a treatment for adult patients with moderate to severe ulcerative colitis. Patients will be treated according to standard of care and will only be included in the study if etrasimod is the best treatment of choice according to the physician and they have not previously taken etrasimod.
All patients will be prescribed etrasimod according to standard of care. Tests and doctor visits will be conducted according to standard of care with the exception of health questionnaires about ulcerative colitis symptoms. These questionnaires will be completed by patients at various timepoints during the study using their mobile phone, tablet, or computer.
The study is 52 weeks with 28 days of safety follow up. The effects of etrasimod will be analyzed for each patient comparing their disease activity prior to the start of etrasimod.
Eligible patients can be included in this study if their physician makes a clinical decision to treat them with etrasimod, as defined by the United States etrasimod prescribing information and independent from the decision to enroll the patient in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe extensive colitis evidenced by:
Prior/Concomitant Therapy:
Drug: Etrasimod
As provided in real world practice
Proportion of patients with symptomatic remission
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0
Time frame: Week 12
Proportion of patients with symptomatic remission
Symptomatic remission is defined as partial Modified Mayo Score (pMMS) stool frequency subscore (SFS) = 0 (or = 1 with a ≥ 1-point decrease from baseline) and (RBS) rectal bleeding subscore = 0
Time frame: Weeks 24, 36, 52
Proportion of patients with symptomatic response
Symptomatic response defined as a decrease from baseline ≥ 30% in pMMS composite RBS and SFS
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with symptomatic response
Symptomatic response defined as a decrease from baseline ≥ 20% in pMMS composite RBS and SFS
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with clinical remission
Clinical remission is defined as a pMMS ≤ 2 points, with no individual subscores \> 1 point.
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with steroid-free symptomatic remission (among all patients and among patients in symptomatic remission)
Steroid-free symptomatic remission is defined as patients in symptomatic remission who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint
Time frame: Weeks 24, 36, 52
Proportion of patients with steroid-free clinical remission (among all patients and among patients in clinical remission)
Steroid-free clinical remission is defined as patients in clinical remission (using a pMMS) who did not take any corticosteroid treatment for 8 weeks prior to the visit/timepoint
Time frame: Weeks 24, 36, 52
Change from baseline in fatigue
Change from baseline in the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score Normalization of fatigue is defined as a FACIT Fatigue score ≥ 40.1
Time frame: Weeks 12, 24, 36, 52
Change from baseline of bowel urgency
Change from baseline in bowel urgency on a 0 (no urgency) - 10 (worst possible urgency) numeric rating scale
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with a clinically meaningful improvement in bowel urgency
Clinically meaningful improvement in bowel urgency is defined as ≥ 3-point decrease from baseline among patients with baseline bowel urgency score ≥ 3
Time frame: Weeks 12, 24, 36, 52
Proportion of patients in bowel urgency remission
Bowel urgency remission is defined as a bowel urgency score ≤ 1 among patients with a baseline bowel urgency score ≥ 3 and the overall population
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with complete bowel urgency remission
Complete bowel urgency remission is defined as a bowel urgency Numeric Rating Scale score = 0
Time frame: Weeks 12, 24, 36, 52
Change from baseline in abdominal pain
Change from baseline in abdominal pain on a 0 (no pain) - 10 (pain as bad as can imagine) numeric rating scale
Time frame: Weeks 12, 24, 36, 52
Proportion of patients with abdominal pain remission
Abdominal pain remission is defined as an abdominal pain Numeric Rating Scale score = 0
Time frame: Weeks 12, 24, 36, 52
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Started Sep 2024 (actual). Primary completion is estimated for Oct 2027, 36 months after the start.
Of 83 industry-sponsored observational studies under Colitis, Ulcerative, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 72. This study's planned 36 months is below that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.